Important MS Medications to Remain Affordable for Australians
The Australian government has confirmed that two essential medications for Multiple Sclerosis (MS), Ocrevus and Kesimpta, will continue to be listed on the Pharmaceutical Benefits Scheme (PBS). This announcement ensures that these life-changing treatments remain affordable and accessible for thousands of patients across the country.
MS Australia, the national peak body for the disease, has welcomed the decision. These medications are classified as high-efficacy disease-modifying therapies. For many patients, they serve as a first-line treatment, helping to manage symptoms and slow the progression of the condition from the early stages of diagnosis.
By keeping these drugs on the PBS, the government significantly reduces the financial burden on families. Without this subsidy, the cost of these specialized treatments would be prohibitively expensive for most Australians. The decision reflects a commitment to supporting those living with chronic health conditions by ensuring they have ongoing access to the latest medical advancements.
This move provides certainty for the MS community, allowing patients to continue their current treatment plans without the fear of sudden price increases. Health advocates emphasize that consistent access to these therapies is vital for maintaining the quality of life and long-term health outcomes for people living with MS in Australia.